GLP-1 drugs like Ozempic are transforming weight loss and diabetes management. But no good deed goes unpunished, and the ...

Patrick Gilligan, a former Blue Cross Blue Shield executive, will succeed Cain Hayes, who left the financially troubled ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new ...

William Tong has taken legal action against two online distributors, Triggered Brand and Made In China, for allegedly selling research-grade GLP-1 weight loss drugs directly to Connecticut consumers ...

According to leaders in obesity and nutrition research, following these key nutrition guidelines will make the most of GLP-1 ...

Are you tired of boring dieting and gruesome workouts? Then, medical weight loss treatment can be a solution for you. But ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

The overturning of the FDA’s lab-developed tests rule is just the tip of the iceberg. With the loss of Chevron deference, ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...